- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Start up Developing Portable and Cost-effective Detectors for Infectious Diseases Including HIV.
Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of sensor products in the medical field, including portable and cost-effective detectors for infectious diseases such as HIV. Alpha Szenszor's co-founders include Steve Lerner, an industry veteran with over 28 years of product development and industrialization experience, and Professor Charles Lieber of Harvard University, world-renowned expert in the field of nanobio sensors.
Nantero's intellectual property includes over 100 patent applications, of which over 25 have already been granted. This intellectual property portfolio is centered around the use of carbon nanotubes in mass manufacturing environments to make a variety of products, including Nantero's NRAM™, a high-density nonvolatile random access memory device. In addition to its work developing NRAM, Nantero is actively licensing its intellectual property portfolio to both startups and established companies for the development of other products that incorporate carbon nanotubes.
Alpha Szenszor is developing a biomedical sensor platform for applications in the field of disease diagnostics and personalized medicine. These products will allow testing of a wide range of diseases such as Cold and Flu, Cancer, Heart Disease, Sexually Transmitted Infections, Food Contamination, and the presence of other life threatening disorders. Alpha Szenszor technology will eliminate the costly and time consuming procedures associated with current diagnostics technology.
Steve Lerner, CEO and Co-Founder of Alpha Szenszor, said, "With our world-class team combining experts in health care, semiconductor processing, and Nantero's scalable carbon nanotube technology, we are poised to bring revolutionary products to market in a very short time frame. We will enable portable disease testing that would be available through local pharmacies and allow anyone to test themselves with total privacy and at a low cost. When placed in the hands of the primary care physicians, we envision our technology becoming part of every patient check-up."
Professor Charles Lieber, Co-Founder of Alpha Szenszor, added, "The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care."
Greg Schmergel, CEO and Co-Founder of Nantero noted "Nantero is approached frequently for licenses to its intellectual property for various fields of use, and we have to pick carefully the right partners who have the capability to bring products to market that will add substantial value to their customers. We believe Alpha Szenszor is such a partner and look forward to working with them."
About Nantero, Inc.
Nantero is a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices. Nantero’s main focus is the development of NRAM™. Nantero is also working with licensees on the development of additional applications of Nantero’s core nanotube-based technology.
More information on Nantero, Inc. is available in English and Japanese at http://www.nantero.com
About Alpha Szenszor
Alpha Szenszor a point of care molecular diagnostics chip company. Alpha Szenszor’s products allow real time, label free detection and quantification of proteins and nucleic acids in a highly scaleable and cost effect platform. Most importantly the company ushers in a digital alternative to current optically based diagnostics. Alpha Szenszor is in the process of raising series A funds, and has already garnered the endorsement of several industry leaders.
For more information, please click here
Suzanne Gibbons-Neff, 617-670-1763
Alpha Szenszor Inc., 978-371-7084
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Intertronics introduce new nanoparticle deagglomeration technology March 15th, 2017
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016